Merck Dumps Sirna RNAi Assets for $175M

Merck has agreed to sell its Sirna Therapeutics assets to Alnylam Pharmaceuticals, a leading RNAi therapeutics company, for an upfront payment of $175 million in cash and equity.

Source: PharmaManufacturing.com - January 14, 2014 Category: Pharmaceuticals Source Type: news